ALG8

Dolichyl pyrophosphate Glc1Man9GlcNAc2 alpha-1,3-glucosyltransferase · Q9BVK2 · ALG8 on Sugi Atlas →

0 patent compounds predicted against ALG8, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to ALG8 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Growth and Development Study of Alglucosidase Alfa PHASE4COMPLETED
China Post-approval Commitment (PAC) Study of Avalglucosidase Alfa in Participants With IOPD PHASE4RECRUITING
Treatment Frequency Reduction in Pompe Disease PHASE4NOT_YET_RECRUITING
Pharmacokinetics of Alglucosidase Alfa in Patients With Pompe Disease PHASE4COMPLETED
Safety and Efficacy of Avalglucosidase Alfa in Patients With Non-classic Pompe Disease Aged ≥ 5 Years PHASE4ACTIVE_NOT_RECRUITING
Switch Over Study of Biosimilar Agalsidase Beta for Fabry Disease PHASE3COMPLETED
Clinical Study for Treatment-naïve IOPD Babies to Evaluate Efficacy and Safety of ERT With Avalglucosidase Alfa PHASE3ACTIVE_NOT_RECRUITING
A Placebo-Controlled Study of Safety and Effectiveness of Myozyme (Alglucosidase Alfa) in Patients With Late-Onset Pompe Disease PHASE3COMPLETED
A Study Comparing ATB200/AT2221 With Alglucosidase Alfa/Placebo in Adult Subjects With Late-onset Pompe Disease PHASE3COMPLETED
Study of Safety, Tolerability and Efficacy of PBGM01 in Pediatric Participants With GM1 Gangliosidosis PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Efficacy of Monosialotetrahexosylganglioside in the Prophylactic Treatment of Bortezomib-induced Peripheral Neuropathy PHASE2UNKNOWN
24-Week Study to Assess the PD, Safety, Tolerability, and PK of GLM101 in Participants With PMM2-CDG PHASE2COMPLETED
A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis PHASE1/PHASE2RECRUITING
A Study of GlcNAc on Tear Production in NGLY1-CDDG PHASE2ACTIVE_NOT_RECRUITING
A Study of the Safety and Pharmacokinetics of rhGAA in Siblings With Glycogen Storage Disease Type II PHASE2COMPLETED
OGT 918-006: A Phase I/II Randomized, Controlled Study of OGT 918 in Patients With Neuronopathic Gaucher Disease PHASE2COMPLETED
Open-Label Extension Study to Assess GLM101 in PMM2-CDG Patients PHASE2ENROLLING_BY_INVITATION
Prevalence of Fabry's Disease in a Population of Patients With Chronic Pain nanCOMPLETED
The Natural History of Alpha-Mannosidosis nanCOMPLETED
Biomarker for Mucolipidosis Disorder Type I, II, III, IV (BioML) nanWITHDRAWN
Using D-Galactose as a Food Supplement in Congenital Disorders of Glycosylation nanCOMPLETED
Expanded Access Use of Myozyme (Alglucosidase Alfa) in Patients With Infantile-onset Pompe Disease nanAPPROVED_FOR_MARKETING
Alglucosidase Alfa Pompe Safety Sub-Registry nanCOMPLETED
Natural History of Glycosphingolipid Storage Disorders and Glycoprotein Disorders nanRECRUITING
Biomarker for Mannosidosis Disease (BioMannosidosis) nanWITHDRAWN
Clinical and Basic Investigations Into Congenital Disorders of Glycosylation nanRECRUITING
Registry Gangliosidoses nanUNKNOWN
Inflammatory Pathways and Cardiac Growth Factors Associated With Fabry Disease Cardiomyopathy nanUNKNOWN
Characterization of the Patient Population With Galactosialidosis nanCOMPLETED
Alglucosidase Alfa Temporary Access Program nanAPPROVED_FOR_MARKETING

Related proteins — ESM-2 sequence neighbours (a ALG8 binder may also engage these)

ProteinNameSimilarity
Q0P5D9 1.000 Q0P5D9 →
O80505 1.000 O80505 →
Q6P8H8 0.998 Q6P8H8 →
Q4IJT0 0.995 Q4IJT0 →
Q10479 0.994 Q10479 →
Q2HA14 0.994 Q2HA14 →
Q2UB20 0.994 Q2UB20 →
Q1DJR8 0.993 Q1DJR8 →
O82244 0.992 O82244 →
Q66IJ4 0.992 Q66IJ4 →
Q500W7 0.992 Q500W7 →
P47088 0.991 P47088 →
Q9FF17 0.991 Q9FF17 →
O43053 0.991 O43053 →
P40351 0.990 P40351 →
Q6FKM3 0.990 Q6FKM3 →
Q5NVS8 0.989 Q5NVS8 →
Q12001 0.989 Q12001 →
Q2U6A4 0.989 Q2U6A4 →
Q9EQY6 0.989 Q9EQY6 →
A8Y3M2 0.989 A8Y3M2 →
Q9P6R5 0.988 Q9P6R5 →
Q8C2R7 0.988 Q8C2R7 →
Q802T2 0.988 Q802T2 →
Q4WVG2 0.988 Q4WVG2 →
Q3T1L5 0.988 Q3T1L5 →
Q9W3V8 0.987 Q9W3V8 →
Q5AWM9 0.987 Q5AWM9 →
Q5EA10 0.986 Q5EA10 →
Q6CJR2 0.986 Q6CJR2 →